Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. Supplemental Materials for Consolidated Financial Results for the Three Months Ended September 30, 2026 (IFRS)
Discloses adjustments reconciling IFRS results to Core results. Revenue was 911.6 billion yen (IFRS) → adjusted to 1,068.1 billion yen (Core cumulative), etc. Operating income was 429.8 billion yen (IFRS), adjusted to 536.1 billion yen cumulative. Outlook for Q4 onward is provided in a separate document; published exchange rates are used as the currency assumptions. Long-term plans and investment metrics are also presented.
Key Figures
- Revenue IFRS results: 9,116 (cumulative) → 9,116 hundred million yen
- Revenue Core cumulative: 10,681 → 10,681 hundred million yen
- Operating income IFRS cumulative: 5,361 → 5,361 hundred million yen
- Net income IFRS cumulative: 3,847 → 3,847 hundred million yen
- Core EPS: 60.30
AI要約
Summary of Results
Chugai Pharmaceutical has disclosed adjustments reconciling IFRS results to Core results. Revenue on a cumulative IFRS basis was 911.6 billion yen, while the supplemental Core cumulative results increased to 1,068.1 billion yen. Operating income was 429.8 billion yen on an IFRS cumulative basis and expanded to 536.1 billion yen on a cumulative Core basis. Research and development expenses and selling, general and administrative expense trends are compared on a Core-results basis, and adjustments such as intangible asset amortization and impairments are described in detail.
Outlook and Financial Indicators
Core results are presented as indicators adjusted for non-recurring items relative to IFRS results, with financial ratios such as ROIC and ROA provided. Exchange rates use the period average market rates stated in the materials. Long-term business investments and changes in R&D spending may affect the trajectory of Core indicators.
Chugai Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
